| scholarly article | Q13442814 |
| P50 | author | Brian Kirkpatrick | Q62574216 |
| P2093 | author name string | Buchanan RW | |
| Carpenter WT Jr | |||
| Alphs LD | |||
| McKenney PD | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 119-123 | |
| P577 | publication date | 1989-11-01 | |
| P1433 | published in | Psychiatry Research | Q15750888 |
| P1476 | title | The Schedule for the Deficit syndrome: an instrument for research in schizophrenia | |
| P478 | volume | 30 |
| Q41061357 | A New Division of Schizophrenia Revealed Expanded Bilateral Brain Structural Abnormalities of the Association Cortices |
| Q44555847 | A Tc-99m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome |
| Q51946448 | A brief smell identification test discriminates between deficit and non-deficit schizophrenia. |
| Q53485776 | A five-year followup study of deficit and nondeficit schizophrenia. |
| Q37233960 | A model of smooth pursuit eye movement deficit associated with the schizophrenia phenotype |
| Q89216323 | A positive take on schizophrenia negative symptom scales: Converting scores between the SANS, NSA and SDS |
| Q54345721 | A prospective longitudinal 10-year study of schizophrenia's three major factors and depression. |
| Q37602601 | A review of reward processing and motivational impairment in schizophrenia |
| Q45122746 | A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients |
| Q51098373 | Affect recognition in deficit syndrome schizophrenia. |
| Q41385344 | Affiliation and neuropsychiatric disorders: the deficit syndrome of schizophrenia |
| Q88607265 | Altered brain gyrification in deficit and non-deficit schizophrenia |
| Q37393929 | Anhedonia in schizophrenia and major depression: state or trait? |
| Q30491345 | Anhedonia in schizophrenia: a review of assessment strategies |
| Q47552143 | Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis |
| Q40872011 | Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia |
| Q73206055 | Apolipoprotein E-varepsilon4 frequency in deficit schizophrenia |
| Q35738993 | Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models |
| Q90622080 | Are Negative Symptoms Merely the "Real World" Consequences of Deficits in Social Cognition? |
| Q37785867 | Assessment of Pharmacotherapy for Negative Symptoms of Schizophrenia |
| Q37451474 | Assessment of trait and state aspects of depression in schizophrenia |
| Q36332243 | Attacking Heterogeneity in Schizophrenia by Deriving Clinical Subgroups From Widely Available Symptom Data |
| Q60646423 | Attentional facilitation of response is impaired for antisaccades but not for saccades in patients with schizophrenia: implications for cortical dysfunction |
| Q33693812 | Atypical antipsychotics in older adults |
| Q24630535 | Avolition and expressive deficits capture negative symptom phenomenology: Implications for DSM-5 and schizophrenia research |
| Q38559235 | Avolition, Negative Symptoms, and a Clinical Science Journey and Transition to the Future. |
| Q47301377 | Avolition-Apathy and White Matter Connectivity in Schizophrenia: Reduced Fractional Anisotropy Between Amygdala and Insular Cortex. |
| Q40766958 | Awareness of Pre-diabetes or Diabetes and Associated Factors in People With Psychosis. |
| Q54364120 | BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample. |
| Q73801263 | Behavioural dysregulation of decision-making in deficit but not nondeficit schizophrenia patients |
| Q44965930 | Borna disease virus and deficit schizophrenia |
| Q45730996 | Borna disease virus and psychiatric disorders. |
| Q34419929 | Borna disease virus antibodies and the deficit syndrome of schizophrenia. |
| Q42663078 | Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment |
| Q47628908 | Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophren |
| Q37451422 | Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs. |
| Q91988283 | Childhood adversity and clinical and psychosocial outcomes in psychosis |
| Q53910913 | Clozapine and negative symptoms. An open study. |
| Q31115350 | Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis. |
| Q36406602 | Comparing EEG Nonlinearity in Deficit and Nondeficit Schizophrenia Patients: Preliminary Data |
| Q44533671 | Components of the smooth pursuit function in deficit and nondeficit schizophrenia |
| Q30433935 | Computerized facial analysis for understanding constricted/blunted affect: initial feasibility, reliability, and validity data |
| Q86823069 | Concepts and methods when considering negative symptom course |
| Q59452498 | Concordance of deficit and non-deficit subtypes in siblings affected with schizophrenia |
| Q35928639 | Confirmatory Factor Analysis and Differential Relationships of the Two Subdomains of Negative Symptoms in Chronically Ill Psychotic Patients |
| Q38809282 | Confirmatory factor analysis of the quality of life scale and new proposed factor structure for the quality of life scale-revised |
| Q40913178 | Construct validity of negative symptoms: an empirical and conceptual review |
| Q51890747 | Context, complexity, and cognitive processing in schizophrenia. |
| Q48508905 | Contingent negative variation in patients with deficit schizophrenia or bipolar I disorder with psychotic features: measurement and correlation with clinical characteristics |
| Q53572453 | Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. |
| Q35818882 | Cortical structural abnormalities in deficit versus nondeficit schizophrenia |
| Q33826006 | Cortical thinning in temporo-parietal junction (TPJ) in non-affective first-episode of psychosis patients with persistent negative symptoms |
| Q33845745 | D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia |
| Q34068005 | D-serine added to antipsychotics for the treatment of schizophrenia |
| Q60959871 | DNA Methylation and Gene Expression of Matrix Metalloproteinase 9 Gene in Deficit and Non-deficit Schizophrenia |
| Q36940145 | Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome |
| Q35284133 | Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome |
| Q89490494 | Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation |
| Q33704198 | Deficit psychopathology and a paradigm shift in schizophrenia research |
| Q97430992 | Deficit schizophrenia and its features are associated with PON1 Q192R genotypes and lowered paraoxonase 1 (PON1) enzymatic activity: effects on bacterial translocation |
| Q50419909 | Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: results of supervised machine learning |
| Q42028994 | Deficit schizophrenia: Concept and validity |
| Q37287211 | Deficit schizophrenia: an update |
| Q37075844 | Deficit schizophrenia: association with serum antibodies to cytomegalovirus |
| Q46156609 | Deficit syndrome in older schizophrenic patients |
| Q89238308 | Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid |
| Q48876125 | Detection of metabolites in the white matter of frontal lobes and hippocampus with proton in first-episode treatment-naïve schizophrenia patients. |
| Q37151244 | Differences in glucose tolerance between deficit and nondeficit schizophrenia |
| Q35785464 | Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia |
| Q36994880 | Disconnection Between Amygdala and Medial Prefrontal Cortex in Psychotic Disorders |
| Q38291334 | Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments |
| Q34443228 | Distinct episodic verbal memory profiles in schizophrenia |
| Q36471475 | Dysfunctional attitudes and expectancies in deficit syndrome schizophrenia |
| Q51907519 | Early Psychosis Prevention and Intervention Centre long-term follow-up study of first-episode psychosis: methodology and baseline characteristics. |
| Q37075944 | Early detection of first-episode psychosis: the effect on 1-year outcome |
| Q43744300 | Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. |
| Q46611106 | Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia |
| Q51778855 | Efficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: a pilot study. |
| Q51890189 | Elevated nailfold plexus visibility aggregates in families and is associated with a specific negative symptom pattern in schizophrenia. |
| Q40783768 | Emotional responding in deficit and non-deficit schizophrenia |
| Q30585254 | Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data. |
| Q56767027 | Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia P |
| Q55280853 | Episodic memory and delayed recall are significantly more impaired in younger patients with deficit schizophrenia than in elderly patients with amnestic mild cognitive impairment. |
| Q50716056 | Executive functioning and psychopathological profile in relatives of individuals with deficit v. non-deficit schizophrenia: a pilot study. |
| Q48606034 | Eye tracking disorder in schizophrenia is characterized by specific ocular motor defects and is associated with the deficit syndrome |
| Q36994844 | Familiality of Psychotic Disorders: A Polynosologic Study in Multiplex Families. |
| Q74292491 | Family characteristics of deficit and nondeficit schizophrenia in the Roscommon Family Study |
| Q84447327 | Family history and obstetric complications in deficit and non-deficit schizophrenia: preliminary results |
| Q33836593 | First-episode psychosis and migration in Italy (PEP-Ita migration): a study in the Italian mental health services |
| Q34405313 | Fluvoxamine as an adjunctive agent in schizophrenia |
| Q44597810 | Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study |
| Q36305230 | Gender Differences in the Physical and Psychological Manifestation of Childhood Trauma and/or Adversity in People with Psychosis. |
| Q50998462 | General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia. |
| Q37602618 | Genes and schizophrenia: from a Festschrift Seminar honoring William T. Carpenter Jr, MD. |
| Q39292622 | Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. |
| Q28376198 | Genetic antecedents of dopamine dysfunction in schizophrenia |
| Q41673368 | Glutamate in schizophrenia: clinical and research implications |
| Q36877510 | Gray matter volume alterations in first-episode drug-naïve patients with deficit and nondeficit schizophrenia. |
| Q99591483 | How to Construct a Bottom-Up Nomothetic Network Model and Disclose Novel Nosological Classes by Integrating Risk Resilience and Adverse Outcome Pathways with the Phenome of Schizophrenia |
| Q36093761 | Hypo-metabolism of the rostral anterior cingulate cortex associated with working memory impairment in 18 cases of schizophrenia |
| Q34502745 | Identifying persistent negative symptoms in first episode psychosis |
| Q47301361 | Impact of Reward and Loss Anticipation on Cognitive Control: An Event-Related Potential Study in Subjects With Schizophrenia and Healthy Controls |
| Q34393630 | Impaired insight in patients with newly diagnosed nonaffective psychotic disorders with and without deficit features |
| Q60192917 | In Schizophrenia, Deficits in Natural IgM Isotype Antibodies Including those Directed to Malondialdehyde and Azelaic Acid Strongly Predict Negative Symptoms, Neurocognitive Impairments, and the Deficit Syndrome |
| Q47550846 | In Schizophrenia, Depression, Anxiety, and Physiosomatic Symptoms Are Strongly Related to Psychotic Symptoms and Excitation, Impairments in Episodic Memory, and Increased Production of Neurotoxic Tryptophan Catabolites: a Multivariate and Machine Le |
| Q60192916 | In Schizophrenia, Increased Plasma IgM/IgA Responses to Gut Commensal Bacteria Are Associated with Negative Symptoms, Neurocognitive Impairments, and the Deficit Phenotype |
| Q89631151 | Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity |
| Q36956508 | Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study |
| Q44692399 | Increased stress reactivity: a mechanism specifically associated with the positive symptoms of psychotic disorder. |
| Q48161538 | Induced gamma activity and event-related coherence in schizophrenia |
| Q36031032 | Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features |
| Q39025362 | Influence of early trauma on features of schizophrenia |
| Q34311294 | Initial development and preliminary validation of a new negative symptom measure: The Clinical Assessment Interview for Negative Symptoms (CAINS) |
| Q51861014 | Insights from the examination of verbal and spatial memory errors in relation to clinical symptoms of patients with recent-onset schizophrenia. |
| Q48102746 | Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: An unbiased cell-counting study |
| Q35559267 | Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback |
| Q60511987 | Is cannabis a risk factor for suicide attempts in men and women with psychotic illness? |
| Q48501607 | Is the Prevalence of the Deficit Syndrome in Schizophrenia Higher than Estimated? Results of a Meta-Analysis. |
| Q34616344 | Low vitamin D levels predict clinical features of schizophrenia |
| Q41725891 | MMPI discriminators of deficit vs. non-deficit recent-onset schizophrenia patients |
| Q73692611 | Male gender is associated with deficit schizophrenia: a meta-analysis |
| Q38440149 | Memory and executive function impairments in deficit syndrome schizophrenia |
| Q57815583 | Minocycline as adjunct therapy for a male patient with deficit schizophrenia |
| Q73206125 | Month of birth in deficit and non-deficit schizophrenic patients |
| Q26786992 | Motivational Deficits in Schizophrenia and the Representation of Expected Value |
| Q35176772 | Motor abnormalities and basal ganglia in schizophrenia: evidence from structural magnetic resonance imaging |
| Q50700399 | Multi-components of evoked-brain potentials in deficit and nondeficit schizophrenia. |
| Q55433586 | Negative Symptom Therapeutics. |
| Q44024286 | Negative symptoms in first episode non-affective psychosis |
| Q33921723 | Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations. |
| Q33820512 | Negative symptoms in schizophrenia |
| Q33364180 | Negative symptoms in schizophrenia: a review |
| Q33707635 | Negative symptoms in schizophrenia: avolition and Occam's razor |
| Q40597326 | Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia |
| Q47587674 | Negative symptoms of psychosis: A life course approach and implications for prevention and treatment |
| Q36698647 | Negative symptoms of schizophrenia: a problem that will not go away |
| Q52618157 | Negative symptoms of schizophrenia: new developments and unanswered research questions. |
| Q37039975 | Negative symptoms, defect state and Huber's basic symptoms: A comparison of the concepts |
| Q36594933 | Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System. |
| Q47575357 | Neural substrate of unrelenting negative symptoms in schizophrenia: a longitudinal resting-state fMRI study |
| Q80433356 | Neuregulin 1: genetic support for schizophrenia subtypes |
| Q37975551 | Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia |
| Q35779544 | Neurocognitive Impairments in Deficit and Non-Deficit Schizophrenia and Their Relationships with Symptom Dimensions and Other Clinical Variables |
| Q38403105 | Neurocognitive functioning in patients with first-episode schizophrenia : results of a prospective 5-year follow-up study. |
| Q33762494 | Neurocognitive functioning of individuals with schizophrenia: using and not using drugs |
| Q48076142 | Neurocognitive impairment in the deficit subtype of schizophrenia |
| Q36244260 | Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia |
| Q41600823 | Neuropsychological Profile of Specific Executive Dysfunctions in Patients with Deficit and Non-deficit Schizophrenia |
| Q31084441 | Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date |
| Q36412864 | Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale |
| Q34312448 | Odor identification, eye tracking and deficit syndrome schizophrenia. |
| Q33950864 | Olfactory hedonic judgment in patients with deficit syndrome schizophrenia |
| Q36213396 | Olfactory performance segregates effects of anhedonia and anxiety on social function in patients with schizophrenia |
| Q35785795 | Olfactory processing, sex effects and heterogeneity in schizophrenia |
| Q34900214 | Paternal age related schizophrenia (PARS): Latent subgroups detected by k-means clustering analysis |
| Q58099454 | Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire |
| Q37076288 | Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia |
| Q46271693 | People living with psychotic illness in 2010: the second Australian national survey of psychosis. |
| Q33950896 | Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study |
| Q36651056 | Persistent negative symptoms in schizophrenia: an overview |
| Q47955421 | Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway. |
| Q74089805 | Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia |
| Q35162552 | Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia |
| Q60460849 | Positive and negative symptoms/syndromes in schizophrenia: reliability and validity of different diagnostic systems |
| Q34830664 | Posttraumatic stress disorder and negative symptoms of schizophrenia |
| Q36954416 | Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site |
| Q45948828 | Prediction of the deficit syndrome from initial deficit symptoms in the early course of schizophrenia. |
| Q35118483 | Predictors of neuropsychological effort test performance in schizophrenia |
| Q33754429 | Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study |
| Q36972791 | Prefrontal neuronal integrity predicts symptoms and cognition in schizophrenia and is sensitive to genetic heterogeneity |
| Q33608652 | Prevalence of 22q11.2 deletions in 311 Dutch patients with schizophrenia |
| Q38675564 | Primary, Enduring Negative Symptoms: An Update on Research |
| Q37661476 | Progress in defining optimal treatment outcome in schizophrenia |
| Q37602615 | Progress in the study of negative symptoms |
| Q47251183 | Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia |
| Q89075389 | Receipt and targeting of evidence-based psychosocial interventions for people living with psychoses: findings from the second Australian national survey of psychosis |
| Q22241700 | Recovery from psychotic illness: a 15- and 25-year international follow-up study |
| Q56955257 | Recruitment of non-patient volunteers with schizophrenia spectrum personality symptoms |
| Q36923834 | Recurrent CNVs disrupt three candidate genes in schizophrenia patients |
| Q33824821 | Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia |
| Q34129176 | Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non-deficit schizophrenia |
| Q90467701 | Reduced mu opioid receptor availability in schizophrenia revealed with [11C]-carfentanil positron emission tomographic Imaging |
| Q48611396 | Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria |
| Q30240167 | Responding to challenges for people with psychotic illness: Updated evidence from the Survey of High Impact Psychosis |
| Q46481970 | Response to unexpected target changes during sustained visual tracking in schizophrenic patients |
| Q34022882 | Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis. |
| Q24185901 | Risperidone (depot) for schizophrenia |
| Q44092149 | SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome |
| Q43559132 | Saccadic and smooth-pursuit eye movements in deficit and non-deficit schizophrenia. |
| Q43466442 | Saccadic eye movement abnormalities in relatives of patients with schizophrenia |
| Q73874580 | Schizophrenia |
| Q59350417 | Schizophrenia is Associated With an Aberrant Immune Response to Epstein-Barr Virus |
| Q35596962 | Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation |
| Q95285848 | Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophrenia |
| Q36861456 | Schizophrenia: disease, syndrome, or dimensions? |
| Q39661444 | Screening for negative symptoms: preliminary results from the self-report version of the Clinical Assessment Interview for Negative Symptoms. |
| Q50479302 | Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. |
| Q35906889 | Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia |
| Q35565079 | Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia |
| Q36817178 | Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms |
| Q71538897 | Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia |
| Q44039337 | Sinistrality in subtypes of schizophrenia |
| Q37628477 | Social Dysfunction and Diet Outcomes in People with Psychosis |
| Q34830420 | Social anhedonia and schizotypy in a community sample: the Maryland longitudinal study of schizotypy |
| Q37075897 | Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction |
| Q39731696 | Striatal function in relation to negative symptoms in schizophrenia. |
| Q40547311 | Structural brain changes are associated with response of negative symptoms to prefrontal repetitive transcranial magnetic stimulation in patients with schizophrenia |
| Q36403000 | Subdomains within the negative symptoms of schizophrenia: commentary |
| Q60192918 | Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia |
| Q30679446 | The Function Biomedical Informatics Research Network Data Repository |
| Q34135398 | The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms |
| Q46701681 | The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity |
| Q36397900 | The NIMH-MATRICS consensus statement on negative symptoms |
| Q49830755 | The Neural Correlates of Negative Symptoms in Schizophrenia: Examples From MRI Literature |
| Q33608454 | The brief negative symptom scale: psychometric properties |
| Q30364829 | The current conceptualization of negative symptoms in schizophrenia |
| Q53719209 | The deficit syndrome in first-admission patients with psychotic and non-psychotic disorders. |
| Q48779127 | The deficit syndrome in the Suffolk County Mental Health Project |
| Q38123067 | The effects of physical exercise in schizophrenia and affective disorders |
| Q37075795 | The factorial structure of the schedule for the deficit syndrome in schizophrenia |
| Q41380354 | The history of the psychopharmacology of schizophrenia |
| Q36169573 | The negative symptoms of schizophrenia: a cognitive perspective |
| Q37918714 | The negative symptoms of schizophrenia: category or continuum? |
| Q52012630 | The reliability of distinguishing primary versus secondary negative symptoms. |
| Q33846109 | The risk of diabetes in deficit schizophrenia |
| Q42152126 | The structural neural substrates of persistent negative symptoms in first-episode of non-affective psychosis: a voxel-based morphometry study |
| Q36299240 | The structure of negative symptoms within schizophrenia: implications for assessment. |
| Q64963554 | The structure of schizophrenic symptoms: a meta-analytic confirmatory factor analysis. |
| Q44779148 | The timing of negative symptom exacerbations in relationship to positive symptom exacerbations in the early course of schizophrenia |
| Q58143055 | Therapeutic Synergism: Optimal Pharmacotherapy and Psychiatric Rehabilitation to Enhance Functional Outcome in Schizophrenia |
| Q34604423 | Toward the Next Generation of Negative Symptom Assessments: The Collaboration to Advance Negative Symptom Assessment in Schizophrenia |
| Q80020192 | Trail making and olfaction in schizophrenia: implications for processing speed |
| Q40048227 | Treating body, treating mind: The experiences of people with psychotic disorders and their general practitioners - Findings from the Australian National Survey of High Impact Psychosis |
| Q36402997 | Treatment of schizophrenia negative symptoms: future prospects |
| Q51782392 | Two subgroups of schizophrenia identified by systematic cognitive neuropsychiatric mapping. |
| Q48049011 | Validation of Turkish version of brief negative symptom scale |
| Q36989822 | Validation of the Korean-Version of the Clinical Assessment Interview for Negative Symptoms of Schizophrenia (CAINS). |
| Q34013742 | Validity of a 'proxy' for the deficit syndrome derived from the Positive And Negative Syndrome Scale (PANSS). |
| Q30400036 | What do we really know about blunted vocal affect and alogia? A meta-analysis of objective assessments. |
| Q37159928 | White matter alterations in deficit schizophrenia. |
| Q35932602 | White matter alterations in first episode treatment-naïve patients with deficit schizophrenia: a combined VBM and DTI study. |
| Q37100393 | Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study |
| Q79351215 | [Comparative evaluation of quality of life in patients with schizophrenia treated with conventional versus atypical neuroleptics: results of a transversal study] |
| Q87096963 | [Psychopathological aspects of negative symptoms in schizophrenia] |
| Q87096954 | [Use of antidepressants in the treatment of negative symptoms of schizophrenia] |
Search more.